Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

H.C. Wainwright analyst raised the price target on Ocugen, Inc. (NASDAQ:OCGN) to $8.00, up from the previous $7.00, while maintaining a Buy rating on the stock. Currently trading at $0.66, the stock ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Bishop asked about upcoming events. Missling outlined the anticipated schizophrenia trial readout for ANAVEX 3-71 in the first half of 2025, the detailed ATTENTION-AD data presentation in April, and ...

EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.

Boca Raton, Florida Wednesday, February 12, 2025, 16:00 Hrs [IST] ...

For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge. A new clinical trial at UVA is aiming to simplify diabetes management by testing an ...